^
Association details:
| Biomarker: | TPM3-NTRK1 fusion |
|---|---|
| Cancer: | Thyroid Gland Papillary Carcinoma |
| Drug: | taletrectinib (AB-106) (TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
US phase 1 first-in-human study of taletrectinib (DS-6051b/AB-106), a ROS1/TRK inhibitor, in patients with advanced solid tumors
Published date:
06/26/2020
Excerpt:
There were 4 patients who achieved confirmed partial responses (two CD74-ROS1+ NSCLC, one TPM3-NTRK1+ thyroid cancer, and one small bowel NET patient)....Only one patient (metastatic TPM3-NTRK1+ papillary thyroid cancer) with an NTRK fusion enrolled to the study, who achieved a DOR of 33.4 months at the time of last tumor assessment...
DOI:
10.1158/1078-0432.CCR-20-1630
Trial ID:
